12:00 AM
 | 
Dec 23, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Kalydeco ivacaftor regulatory update

Vertex said FDA accepted and granted Priority Review to an sNDA for Kalydeco ivacaftor as monotherapy to treat cystic fibrosis in patients ages >=6 years who have at least 1 non-G551D gating mutation in the...

Read the full 155 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >